Kitajima S, Asahina H, Chen T, et al. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. Cancer Cell. 2018;34(3):439-452.e6. doi:10.1016/j.ccell.2018.08.009
Adeegbe DO, Liu S, Hattersley MM, et al. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in -Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res. 2018;6(10):1234-1245. doi:10.1158/2326-6066.CIR-18-0077
Aguirre AJ, Hahn WC. Synthetic Lethal Vulnerabilities in -Mutant Cancers. Cold Spring Harb Perspect Med. 2018;8(8). doi:10.1101/cshperspect.a031518
Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378-384. doi:10.1038/nature21386
Ladas I, Fitarelli-Kiehl M, Song C, et al. Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. Clin Chem. 2017;63(10):1605-1613. doi:10.1373/clinchem.2017.272849
Wong GS, Zhou J, Bin Liu J, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018;24(7):968-977. doi:10.1038/s41591-018-0022-x
Yuan TL, Amzallag A, Bagni R, et al. Differential Effector Engagement by Oncogenic KRAS. Cell Rep. 2018;22(7):1889-1902. doi:10.1016/j.celrep.2018.01.051
Xu H, Lee MS, Tsai PY, et al. Ablation of insulin receptor substrates 1 and 2 suppresses -driven lung tumorigenesis. Proc Natl Acad Sci U S A. 2018;115(16):4228-4233. doi:10.1073/pnas.1718414115
Awad MM, Liu S, Rybkin II, et al. Acquired Resistance to KRAS Inhibition in Cancer. N Engl J Med. 2021;384(25):2382-2393. doi:10.1056/NEJMoa2105281
Liu Y, Sethi NS, Hinoue T, et al. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell. 2018;33(4):721-735.e8. doi:10.1016/j.ccell.2018.03.010